Well of course...because its beneficial, why wouldnt our evil lords and masters want it banned or to come at a cost of 600% more. They cant have us healthy unless it makes us more poor. Gotta walk that fine line w the cattle
Honestly such a fucking disgusting agencyWhoever will need to change the way they import their peptides to match how AAS are brought into the country. Customs are going to start siezing packages coming to and from non "greenlit" companies. As it stands now, or as it stood I should say. RUO shipments could come in based on the research use only guidelines. Now that is illegal. AAS have always came in under the radar with whatever measures they use to avoid detection. Any persistent company here will have to do the same. As best I understand it anyway.
You're right about their motivation and right about how disgusting they are, but youre not right about the rest...Now, peptides are in the same category to customs as tren or anadrol, so they must be gotten in illegally same as AAS as opposed to getting them in legally through Research Use Only means.So when they were just selling Tren and Anadrol which are actually dangerous drugs horrible for your health the FDA didn't say shit to them, but when they start selling GLP1s the FDA says thats a bridge too far?
Overstates the existence of new sweeping 2026 regulatory actions. Describes systems (like a GLP-1-specific “Green List”) that do not match standard FDA import framework. Frames longstanding regulatory authority as brand-new law.AI Fact Check... That article is mostly exaggerated.
Here is a point-by-point accuracy check of the claims in the article you provided:
1) BIOSECURE Act / Supply Chain Restrictions
Claim:
The BIOSECURE Act takes effect throughout 2026 and restricts U.S. entities from sourcing biotechnology equipment or services from “companies of concern,” forcing migration to FDA-registered facilities.
Assessment: Partially accurate, but overstated and somewhat misleading.
The BIOSECURE Act has been proposed in Congress to restrict U.S. government contracting with certain foreign biotechnology firms considered national security risks (primarily Chinese companies).
However:
It primarily targets federal procurement and federally funded entities, not all U.S. private importers.
It is not a blanket FDA import rule.
It does not automatically require all private importers to move to FDA-registered facilities, though GMP/FDA registration has always been required for lawful drug manufacturing.
Bottom line: The Act is real policy movement, but the article exaggerates its scope and presents it as a sweeping private-sector import crackdown.
2) Import Alert 66-80 / “Green List” for GLP-1 APIs
Claim:
FDA created a “Green List” specifically for GLP-1 APIs under Import Alert 66-80; CBP now automatically seizes any shipment not from a Green List manufacturer via DWPE.
Assessment: Mostly inaccurate.
Facts:
Import Alert 66-80 does exist. It allows Detention Without Physical Examination (DWPE) for certain unapproved or misbranded drugs.
DWPE has existed for many years; it is not new.
FDA import alerts typically include:
A Red List (firms subject to automatic detention).
Sometimes a Green List (firms removed from detention after demonstrating compliance).
However: There is no publicly established “GLP-1 Green List” category specific to semaglutide or tirzepatide APIs.
Shipments are not automatically seized merely because a manufacturer is “not on a Green List.”
DWPE applies when a product appears to violate the FD&C Act (unapproved new drug, misbranding, adulteration, etc.).
Bottom line:
Import Alert 66-80 is real and DWPE is real — but the description of a new GLP-1-specific Green List system is not supported by standard FDA import procedures.
3) Closure of the “Research Use Only” (RUO) Loophole
Claim:
Labeling products as “Research Use Only” or “Not for Human Consumption” no longer shields vendors if intended use is therapeutic.
Assessment: Largely accurate.
The FDA has long applied the “Intended Use Doctrine.”
If marketing materials, websites, dosing guides, or communications imply human therapeutic use, FDA may classify the product as:
An unapproved new drug
Or misbranded under the FD&C Act
The FDA and DOJ have indeed increased enforcement against peptide vendors marketing “research chemicals” that are clearly intended for human use.
Important nuance:
This is not new law in 2026 — it’s longstanding enforcement authority.
What may have changed is enforcement intensity, not legal framework.
Bottom line: Substantively correct in principle, but framed as a new rule when it is longstanding regulatory doctrine.
4) Elimination of Compounding Categories (BPC-157, Thymosin Beta-4)
Claim:
By early 2026, FDA moved certain peptides (e.g., BPC-157, TB-4) into prohibited status for compounding under Section 503A.
Assessment: Partially accurate but oversimplified.
Key regulatory reality:
Under Section 503A, pharmacies may compound substances that:
Are components of FDA-approved drugs, OR
Appear on the 503A Bulk Drug Substances List, OR
Are nominated and under FDA review (in some circumstances).
Peptides like:
BPC-157
Thymosin Beta-4
have generally:
Not been FDA-approved drugs.
Not been formally included on the 503A bulk substances list.
FDA has issued warning letters regarding compounding of certain peptides due to lack of safety/efficacy data.
However:
There is no single formal “prohibited status announcement” eliminating an entire category in one stroke.
Enforcement has been piecemeal via warning letters, guidance documents, and risk-based prioritization.
Bottom line: Enforcement risk has increased, but the article frames it as a categorical regulatory ban event, which is not how FDA typically operates.
Overall Credibility Assessment
The article:
✔ Mixes real regulatory mechanisms (DWPE, Intended Use Doctrine, 503A rules).
✔ Correctly identifies increased scrutiny around GLP-1 APIs and peptides.
High-Level Conclusion
This appears to be:
A policy-adjacent summary written for the peptide / gray-market GLP-1 audience,
Combining real enforcement mechanisms with speculative or exaggerated interpretations,
Possibly intended to create urgency or justify supply disruptions.
It is not outright fabricated, but it is not technically precise and contains exaggerations.
No disrespect, but you need to drop whatever POS AI you used for that bunch of nonsense it fed you. Just Google "FDA Import Alert 66-80" which is the actual law or guideline they made and it absolutely states that there is a green list of companies and even states how a company can be taken off for breaching the agreement.AI Fact Check... That article is mostly exaggerated.
Here is a point-by-point accuracy check of the claims in the article you provided:
1) BIOSECURE Act / Supply Chain Restrictions
Claim:
The BIOSECURE Act takes effect throughout 2026 and restricts U.S. entities from sourcing biotechnology equipment or services from “companies of concern,” forcing migration to FDA-registered facilities.
Assessment: Partially accurate, but overstated and somewhat misleading.
The BIOSECURE Act has been proposed in Congress to restrict U.S. government contracting with certain foreign biotechnology firms considered national security risks (primarily Chinese companies).
However:
It primarily targets federal procurement and federally funded entities, not all U.S. private importers.
It is not a blanket FDA import rule.
It does not automatically require all private importers to move to FDA-registered facilities, though GMP/FDA registration has always been required for lawful drug manufacturing.
Bottom line: The Act is real policy movement, but the article exaggerates its scope and presents it as a sweeping private-sector import crackdown.
2) Import Alert 66-80 / “Green List” for GLP-1 APIs
Claim:
FDA created a “Green List” specifically for GLP-1 APIs under Import Alert 66-80; CBP now automatically seizes any shipment not from a Green List manufacturer via DWPE.
Assessment: Mostly inaccurate.
Facts:
Import Alert 66-80 does exist. It allows Detention Without Physical Examination (DWPE) for certain unapproved or misbranded drugs.
DWPE has existed for many years; it is not new.
FDA import alerts typically include:
A Red List (firms subject to automatic detention).
Sometimes a Green List (firms removed from detention after demonstrating compliance).
However: There is no publicly established “GLP-1 Green List” category specific to semaglutide or tirzepatide APIs.
Shipments are not automatically seized merely because a manufacturer is “not on a Green List.”
DWPE applies when a product appears to violate the FD&C Act (unapproved new drug, misbranding, adulteration, etc.).
Bottom line:
Import Alert 66-80 is real and DWPE is real — but the description of a new GLP-1-specific Green List system is not supported by standard FDA import procedures.
3) Closure of the “Research Use Only” (RUO) Loophole
Claim:
Labeling products as “Research Use Only” or “Not for Human Consumption” no longer shields vendors if intended use is therapeutic.
Assessment: Largely accurate.
The FDA has long applied the “Intended Use Doctrine.”
If marketing materials, websites, dosing guides, or communications imply human therapeutic use, FDA may classify the product as:
An unapproved new drug
Or misbranded under the FD&C Act
The FDA and DOJ have indeed increased enforcement against peptide vendors marketing “research chemicals” that are clearly intended for human use.
Important nuance:
This is not new law in 2026 — it’s longstanding enforcement authority.
What may have changed is enforcement intensity, not legal framework.
Bottom line: Substantively correct in principle, but framed as a new rule when it is longstanding regulatory doctrine.
4) Elimination of Compounding Categories (BPC-157, Thymosin Beta-4)
Claim:
By early 2026, FDA moved certain peptides (e.g., BPC-157, TB-4) into prohibited status for compounding under Section 503A.
Assessment: Partially accurate but oversimplified.
Key regulatory reality:
Under Section 503A, pharmacies may compound substances that:
Are components of FDA-approved drugs, OR
Appear on the 503A Bulk Drug Substances List, OR
Are nominated and under FDA review (in some circumstances).
Peptides like:
BPC-157
Thymosin Beta-4
have generally:
Not been FDA-approved drugs.
Not been formally included on the 503A bulk substances list.
FDA has issued warning letters regarding compounding of certain peptides due to lack of safety/efficacy data.
However:
There is no single formal “prohibited status announcement” eliminating an entire category in one stroke.
Enforcement has been piecemeal via warning letters, guidance documents, and risk-based prioritization.
Bottom line: Enforcement risk has increased, but the article frames it as a categorical regulatory ban event, which is not how FDA typically operates.
Overall Credibility Assessment
The article:
✔ Mixes real regulatory mechanisms (DWPE, Intended Use Doctrine, 503A rules).
✔ Correctly identifies increased scrutiny around GLP-1 APIs and peptides.
High-Level Conclusion
This appears to be:
A policy-adjacent summary written for the peptide / gray-market GLP-1 audience,
Combining real enforcement mechanisms with speculative or exaggerated interpretations,
Possibly intended to create urgency or justify supply disruptions.
It is not outright fabricated, but it is not technically precise and contains exaggerations.
Ok, thank you sir. I'm not disrespected. I didnt create the AI, but I'm sorry if you found my post offensive.
Sounds like a reasonable statement. However someone seized a shipment of my peps in January.They ain’t grabbing my 5”x4”x6” packages. It’s not worth their time. It’s been illegal to ship steroids into the states since the 90’s. How’s that been affecting anyone. People need to simmer down.
I guess what might make it more difficult is the grey area peptide market is actually huge. A few kilos of raw aas is literally enough for all the drug addicts on this entire forum. Cant say the same about the millions of soccer moms on GLP1s
Its all about the $$$$$$$So when they were just selling Tren and Anadrol which are actually dangerous drugs horrible for your health the FDA didn't say shit to them, but when they start selling GLP1s the FDA says thats a bridge too far?
